Unlocking the therapeutic potential of ATR inhibitors: Advances, challenges, and opportunities in cancer therapy

This publication has 9 references indexed in Scilit:

• Targeting ATR in patients with cancer
  Nature Reviews Clinical Oncology, 2024
• Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
  Nature Medicine, 2023
• First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
  Cancer Discovery, 2020
• ATR is essential for preservation of cell mechanics and nuclear integrity during interstitial migration
  Nature Communications, 2020
• ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer
  Cancer Research, 2020
• A decade of clinical development of PARP inhibitors in perspective
  Annals of Oncology, 2019
• State-of-the-art strategies for targeting the DNA damage response in cancer
  Nature Reviews Clinical Oncology, 2018
• Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
  Cell Stem Cell, 2017
• ATR: an essential regulator of genome integrity
  Nature Reviews Molecular Cell Biology, 2008